Not buying more ABBV now due to limited upside at record highs; holding existing position for yield.

We begin with a true giant in the healthcare sector , a traditional defensive stock that generates profits and prints money for long-term investors. It is the biopharmaceutical giant “AbbVie” , which carries the symbol ABBV, and on which the Saudi central bank doubled its bet last quarter, increasing its stake by about 90% and spending an estimated $14 million in just one quarter.

In fact, I own shares in AbbVie that I bought many years ago , but if you follow it like I do, you know that the biggest threat surrounding this stock has always been the scary specter of the expiration of the patent for Humira, which was the best-selling drug on earth before it lost its exclusivity in the United States .

Yes, it is a real concern. In the last quarter, for example, drug sales fell by about 36%. But AbbVie didn't stand idly by and watch its revenues evaporate. Instead, they built a completely replacement engine to compensate for that.

For example, the next- generation immunosuppressants , "Skyrizi" and "Rinvoq", are achieving several times greater total sales, with growth approaching 25% year-on-year. The administration even believes it will generate more than $31 billion for the entire year.

And again , that's just two drugs . Typically, a drug is considered a "blockbuster " if it achieves sales of just $1 billion. These two properties will generate approximately 30 times that amount.

And they don't stop there either . In the field of neuroscience, for example, their migraine medication has jumped by more than 30% year-on-year and has recently achieved success in phase three trials for treating menstrual-related migraines, potentially opening up a market of millions of new patients.

Thanks to acquisitions, AbbVie's portfolio of projects has also grown tremendously over the years. Such as the approximately $11 billion it invested in acquiring "Apogee Therapeutics" to bring in late-stage filters for eczema and asthma treatments as well.

All of this has provided significant growth to their financial data, with sales more than doubling in the last quarter, reaching approximately $17 billion. While adjusted earnings per share also rose by about 23%, analysts believe this growth will certainly continue in the long term.

Because they are generating huge profits with free cash flow projected to exceed $20 billion this year , they have been able to maintain their position as the "dividend king" by increasing payments for five consecutive decades.

However, I personally am not buying any additional shares at the moment. The reason is very simple. The stock has seen a very strong rise in recent years. Because I bought a long time ago at much lower prices, I have actually been able to secure a dividend yield of around 7%, if you can believe it.

It's one of my favorites. But today, that return would give less than 3% to any new investors buying at the current high prices.

As I said, I've bought before, so my base cost is much lower . This means that my dividend yield is actually much higher based on what I paid out. While the valuation is still somewhat reasonable today thanks to all this growth in net profits, especially when looking at the price- to-earnings ratio for future growth, it still looks very attractive. It's even lower than the sector average.

But despite that, I still feel a kind of hesitation, I don't know. I feel I can only believe that the upside potential is extremely limited at these high levels, with the stock trading near record highs.

So, I'm going to put them in the middle for now , and third place is where I feel most comfortable right now, at least until we see the other names on this list.